http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-9608207-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_172fc86cea568bca89b921753cb00cae
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43536
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-58
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
filingDate 1996-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5279ad3436013967af0d66b054810da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50d236dd25140de92845dd0ead880c74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f95edf00f179f9311cab56c438fcde12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad756ea502de22fbdca43dd26a1bc9b7
publicationDate 2000-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-9608207-A
titleOfInvention Fibrin crosslinking inhibitors and / or transglutaminases
abstract <B> FIBRIN AND / OR TRANSGLUTAMINASE BINDING INHIBITORS <D> Inhibitors that can be obtained from tissues or secretions of leeches typically of the order Rhychobdellida have the following terminal sequence: NH ~ 2 ~ -Lys-Leu-Leu-Pro-Cys -Lys-Glu-Y-His-Gln-Gly-Ile-Pro-Asn-Pro-Arg, where Y represents any amino acid sequence; or a salt, derivative or bioprecursor of the pharmaceutically acceptable sequence, or an analog or homologue thereof. Due to their extreme potency in the nanomolar range, inhibitors can be used to treat various diseases where protein cross-linking is important. The inhibitors can be used in the treatment of Crohn's disease, tumor implantation, arteriosclerosis, trombic microangiopathy, fibrous skin growth, acne, scarring, glomerulonephritis, cataracts or infection with microfilarial nematodes. In particular, inhibitors can be used to reduce vessel stability so that they are more subject to lysis by thrombolytic agents.
priorityDate 1995-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415966231
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439199

Total number of triples: 29.